Health·2,845 stories
Entrada Therapeutics’ latest exon‑skipping candidate for Duchenne muscular dystrophy fell short of efficacy expectations in an early‑stage trial, putting its competitive edge at risk as the field fill
Helmholtz Munich’s team, led by Prof Timo D. Müller, engineered a ‘Trojan‑horse’ obesity drug that fuses GLP‑1/GIP signaling with the pan‑PPAR agonist lanifibranor. In mouse experiments the hybrid cut
A University of Connecticut trial of 66 women over 65 found that combining a testosterone gel with exercise selectively reduced dangerous visceral fat after hip fractures, reversing a typical post-inj
Italian drugmaker Angelini Pharma is acquiring U.S. rare‑disease specialist Catalyst Pharmaceuticals for about $4.1 billion in cash, a 28% premium over recent share prices. The deal gives Angelini a d
A large German twin study finds that IQ is about three‑quarters genetically determined and that genetics explain up to 98% of the link between IQ and adult socioeconomic status. Even twins raised toge
PeaceHealth’s plan to replace its long‑standing Oregon emergency physicians with the national staffing firm ApolloMD sparked a wave of opposition from clinicians, lawmakers and community leaders. Afte
MIT neuroscientists discovered that roughly 30% of synapses in the adult mouse cortex are 'silent synapses' — dormant connections lying in wait until new learning activates them, overturning the long-
Researchers at the University of Edinburgh and the UK Dementia Research Institute have shown that lacunar strokes – which affect about 35,000 Britons each year – stem from the widening of small brain
A worldwide push to map the hidden ‘dark proteome’ has uncovered a trove of tiny mitochondrial proteins that may be key to heart disease. Using ribosome profiling on 80 donor hearts, systems biologist
Gene therapy leaders at a Rome conference pointed to recent FDA approvals for rare‑disease drugs from Rocket and Regeneron as a bright spot, but the abrupt departure of Vinay Prasad, the FDA’s top gen
A 72-year-old retired opera singer who hid her deafness for three decades is backing a nationwide NHS trial of bilateral cochlear implants that could overturn NICE guidelines currently restricting mos
A brief pre‑surgery course of pembrolizumab has halted cancer recurrence for nearly three years in high‑risk stage 2/3 colorectal patients, overturning the traditional surgery‑then‑chemo paradigm. The
A decade‑long Finnish trial shows that partial meniscectomy, one of the world’s most common knee surgeries, provides no benefit over sham procedures. Moreover, patients who received the operation expe
A decade-long study of 3,231 Finnish adults found that highly inconsistent bedtimes at age 46 roughly doubled the risk of major cardiovascular events, especially among those sleeping under eight hours
An HHS spokesperson says the FDA pulled three large‑scale safety studies on COVID‑19 and shingles vaccines after the authors were judged to have over‑reached their data, despite the papers being accep
STAT+ teases a deep dive into AI diagnostic performance, but the article is mainly a subscription plug and a preview of an interview with OpenEvidence CTO Zachary Ziegler at the upcoming Breakthrough
A Rice University study finds that people who lose weight using GLP-1 drugs like Ozempic and Wegovy are judged more harshly than those who lose weight through diet and exercise—or even those who never
A new PatientView survey of 2,400 patient groups across 35 countries finds that 57% now rate drugmakers as excellent or good – a modest rise from 56% last year but still below the 60% peak in 2022. Th
NHS England will hide its taxpayer‑funded open‑source software by May 11, citing AI‑driven hacking risks from Anthropic’s Mythos, sparking backlash from experts, an open letter and concerns over secur
A single 25 mg dose of psilocybin reshaped brain structure in healthy volunteers, with diffusion MRI showing denser front‑to‑midbrain tracts a month later. The change coincided with heightened EEG ent
Curated health stories, every morning. Free.
No spam. Unsubscribe anytime.